Breast Cancer | Oncology Today with Dr Neil Love: Use of Genomic Classifiers to Inform Clinical Decision-Making for Patients with Early Breast Cancer

Research To Practice | Oncology Videos

A virtual roundtable discussion with Drs Joseph A Sparano and Eric P Winer reviewing recent innovations in the treatment of early breast cancer.

• Comparison of patient risk classifications by genomic assays for patients with early-stage breast cancer (00:00)
• Prognostic gene expression assays in breast cancer: Are 2 better than 1? (06:13)
• Implications of gene expression assay results for therapeutic decision-making (07:51)
• Design and results of the Phase III TAILORx trial evaluating chemoendocrine therapy versus endocrine therapy alone for patients with ER-positive, HER2-negative, node-negative breast cancer and an intermediate 21-gene assay Recurrence Score® (RS) (11:19)
• Clinical implications of the TAILORx trial for treatment decision-making for patients older than 50 with ER-positive early breast cancer (EBC) (16:24)
• Prediction of chemotherapy benefit by RS for patients 50 years or younger with ER-positive EBC (17:51)
• Benefit with the addition of ovarian suppression to endocrine therapy for premenopausal women with ER-positive breast cancer at high risk for recurrence (22:18)
• Case (Dr Winer): A woman in her early 60s with Grade III ER-positive, HER2-negative, node-negative breast cancer has a 2.1-cm tumor and a RS of 25 (24:30)
• Risk of recurrence and benefit from chemotherapy for postmenopausal women with EBC (27:57)
• Significance of clinical risk category in prognosis and prediction of chemotherapy benefit by age and RS in the TAILORx trial (33:06)
• Perspective on the use of Ki-67 as a biomarker in breast cancer (36:11)
• Clinical and genomic risk to guide the use of adjuvant therapy for breast cancer (37:55)
• Implications of the TAILORx trial results for the use of neoadjuvant endocrine therapy (40:10)
• Case (Dr Sparano): A woman in her early 60s with Stage IIA ER-positive, HER2-negative lobular breast cancer, a RS of 19 and a high ESR1 RNA score receives adjuvant docetaxel/cyclophosphamide followed by anastrozole (45:45)
• Tolerability and quality of life during treatment with chemotherapy (50:09)
• Change in perspective for oncology professionals diagnosed with cancer (50:50)
• Impact of the RS-pathology-clinical (RSPC) score on the assessment of recurrence risk for patients with breast cancer (55:01)
• Case (Dr Winer): A woman in her late 30s with Grade II ER-positive, node-negative breast cancer and a RS of 20 receives treatment with ovarian suppression and tamoxifen (58:12)
• Case (Dr Winer): A woman in her late 50s with ER-positive lobular breast cancer, a 5.2-cm tumor, 1 palpable lymph node and a RS of 8 receives neoadjuvant endocrine therapy and a CDK4/6 inhibitor on a clinical trial (1:03:43)
• Case (Dr Sparano): A woman in her early 60s with Stage IIA ER-positive, node-positive right breast cancer (RS 7) and Stage IA left breast cancer experiences a good response to adjuvant anastrozole alone (1:07:21)
• Prognostic effect of the 21-gene assay RS for patients with high-risk ER-positive EBC and 1 to 3 positive nodes (1:10:19)

CME information and select publications